TABLE 13, [Results of regression analyses for costs and QALYs]. - Early high-dose cryoprecipitate to reduce mortality in adult patients with traumatic haemorrhage: the CRYOSTAT-2 RCT with cost-effectiveness analysis

	Coefficient	95% CI	p-value	Marginal effect
*Total cost of hospital stay*
Intervention arm	−0.017	−0.109 to 0.073	0.705	−310
*Total cost for blood products*
Intervention arm	0.276	0.163 to 0.389	< 0.0001	519
*Total cost*
Intervention arm	0.011	−0.074 to 0.096	0.803	210
*QALYs (without imputation)*
Intervention arm	0.00004	−0.0016 to 0.0015	0.848
*QALYs (with imputation)*
Intervention arm	0.0005	−0.002 to 0.008	0.455

Cover of Early high-dose cryoprecipitate to reduce mortality in adult patients with traumatic haemorrhage: the CRYOSTAT-2 RCT with cost-effectiveness analysis

Early high-dose cryoprecipitate to reduce mortality in adult patients with traumatic haemorrhage: the CRYOSTAT-2 RCT with cost-effectiveness analysis.

Health Technology Assessment, No. 28.76.

Curry N, Davenport R, Thomas H, et al.

Southampton (UK): National Institute for Health and Care Research; 2024 Nov.

This work was produced by Curry et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/. For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.